Christian  Klemt net worth and biography

Christian Klemt Biography and Net Worth

CFO of uniQure
Mr. Christian Klemt has served as Chief Accounting Officer since August 2017. In 2020 he was named General Manager of our Amsterdam office.  

Since joining uniQure in 2015, Mr. Klemt has transformed the Finance and Accounting functions at uniQure, dramatically improved the internal control environment, and enhanced the financial planning and analysis functions. He also oversaw the Company's transition to a domestic U.S. filer and conversion to U.S. Generally Accepted Accounting Principles.

Mr. Klemt holds a Master's degree in Business Administration from the University of Muenster, Germany and is qualified as a German Certified Public Accountant and Tax Advisor.

What is Christian Klemt's net worth?

The estimated net worth of Christian Klemt is at least $3.13 million as of March 4th, 2025. Mr. Klemt owns 217,730 shares of uniQure stock worth more than $3,126,603 as of March 26th. This net worth estimate does not reflect any other assets that Mr. Klemt may own. Additionally, Mr. Klemt receives an annual salary of $575,460.00 as CFO at uniQure. Learn More about Christian Klemt's net worth.

How old is Christian Klemt?

Mr. Klemt is currently 51 years old. There are 4 older executives and no younger executives at uniQure. The oldest executive at uniQure is Dr. Walid Abi-Saab M.D., Chief Medical Officer, who is 59 years old. Learn More on Christian Klemt's age.

What is Christian Klemt's salary?

As the CFO of uniQure, Mr. Klemt earns $575,460.00 per year. There are 2 executives that earn more than Mr. Klemt. The highest earning executive at uniQure is Mr. Matthew Craig Kapusta, CEO & Executive Director, who commands a salary of $1,020,000.00 per year. Learn More on Christian Klemt's salary.

How do I contact Christian Klemt?

The corporate mailing address for Mr. Klemt and other uniQure executives is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. uniQure can also be reached via phone at (120) 240-6000 and via email at investors@uniqure. Learn More on Christian Klemt's contact information.

Has Christian Klemt been buying or selling shares of uniQure?

Within the last three months, Christian Klemt has sold $293,864.84 in uniQure stock. Most recently, Christian Klemt sold 10,438 shares of the business's stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $10.29, for a transaction totalling $107,407.02. Following the completion of the sale, the chief financial officer now directly owns 217,730 shares of the company's stock, valued at $2,240,441.70. Learn More on Christian Klemt's trading history.

Who are uniQure's active insiders?

uniQure's insider roster includes Ricardo Dolmetsch (Insider), Robert Gut (Director), Matthew Kapusta (CEO), Christian Klemt (CFO), and Alexander Kuta, III (VP). Learn More on uniQure's active insiders.

Are insiders buying or selling shares of uniQure?

In the last twelve months, insiders at the biotechnology company sold shares 12 times. They sold a total of 104,493 shares worth more than $1,042,573.95. The most recent insider tranaction occured on March, 4th when CEO Matthew C Kapusta sold 28,341 shares worth more than $291,628.89. Insiders at uniQure own 4.7% of the company. Learn More about insider trades at uniQure.

Information on this page was last updated on 3/4/2025.

Christian Klemt Insider Trading History at uniQure

Christian Klemt Buying and Selling Activity at uniQure

This chart shows Christian Klemt's buying and selling at uniQure by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$294ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$200k$0$200kTotal Insider BuyingTotal Insider Selling

uniQure Company Overview

uniQure logo
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Read More

Today's Range

Now: $14.36
Low: $14.12
High: $14.97

50 Day Range

MA: $13.83
Low: $10.90
High: $16.21

2 Week Range

Now: $14.36
Low: $3.73
High: $19.18

Volume

682,939 shs

Average Volume

1,623,756 shs

Market Capitalization

$776.55 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.36